Join Growin Stock Community!

朗齊生醫*6876.TW Overview

TW StockBiotech. & Medical
(No presentation for 6876)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

朗齊生醫*（6876）Overall Performance

朗齊生醫*（6876）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

朗齊生醫*（6876） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

朗齊生醫*（6876）Key Information

朗齊生醫*（6876）Profile

LAUNXP Biomedical Co. Ltd. is engaged in the development of medicines for tumor therapies. It also offers anti-cancer and antiproliferative drugs including virus-like nanoparticles and nanoparticles. The company was founded on September 24, 2015 and is headquartered in Taichung, Taiwan.

朗齊生醫*（6876）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.73
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
96285.68
PB Ratio
3.71
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-1709.09%
Net Margin
-1626445.45%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.73
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
96285.68
PB Ratio
3.71
Price-to-FCF
-
Gross Margin
-1709.09%
Net Margin
-1626445.45%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6876

朗齊生醫*

22.10D

1.13%

(0.01)

  • When is 6876's latest earnings report released?

    The most recent financial report for 朗齊生醫* (6876) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6876's short-term business performance and financial health. For the latest updates on 6876's earnings releases, visit this page regularly.

  • How much cash does 6876 have?

    At the end of the period, 朗齊生醫* (6876) held Total Cash and Cash Equivalents of 246.08M, accounting for 0.43 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.